Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.30207593
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, Phase 2/3 trial. Lancet. 2019;393(10184):1948–1957.30982686
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.16822992
   PubMed Web of Science ®Google Scholar
• Witters LA. The blooming of the French lilac. J Clin Invest. 2001;108(8):1105–1107.11602616
   PubMed Web of Science ®Google Scholar
• Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes. 2014;7:241–253.25018645
   PubMedGoogle Scholar
• Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46(13):2369–2380.20656475
   PubMed Web of Science ®Google Scholar
• Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24(9):469–480.23773243
   PubMed Web of Science ®Google Scholar
• Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and alzheimer’s-like changes. Neuropharmacology. 2011;60(6):910–920.21277873
   PubMed Web of Science ®Google Scholar
• Ahmed FW, Rider R, Glanville M, Narayanan K, Razvi S, Weaver JU. Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. Cardiovasc Diabetol. 2016;15(1):116.27561827
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–1305.15849206
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(7):2347–2353.22523334
   PubMed Web of Science ®Google Scholar
• Bhaw-Luximon A, Jhurry D. Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. J Cancer Res Clin Oncol. 2016;142(10):2159–2171.27160287
   PubMed Web of Science ®Google Scholar
• Gong J, Robbins LA, Lugea A, Waldron RT, Jeon CY, Pandol SJ. Diabetes, pancreatic cancer, and metformin therapy. Front Physiol. 2014;5:426.25426078
   PubMed Web of Science ®Google Scholar
• Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011;11:20.21241523
   PubMed Web of Science ®Google Scholar
• Ruiter R, Visser LE, van Herk-sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care. 2012;35(1):119–124.22100960
   PubMed Web of Science ®Google Scholar
• Kim YI, Kim SY, Cho SJ, et al. Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: a nationwide cohort study. Aliment Pharmacol Ther. 2014;39(8):854–863.24612291
   PubMed Web of Science ®Google Scholar
• Murff HJ, Roumie CL, Greevy RA, et al. Metformin use and incidence cancer risk: evidence for a selective protective effect against liver cancer. Cancer Causes Control. 2018;29(9):823–832.30022336
   PubMed Web of Science ®Google Scholar
• Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. clinical practice research datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37(9):2522–2532.24898303
   PubMed Web of Science ®Google Scholar
• Valent F. Diabetes mellitus and cancer of the digestive organs: an Italian population-based cohort study. J Diabetes Complications. 2015;29(8):1056–1061.26275864
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY). 2016;8(8):1636–1649.27587088
   PubMedGoogle Scholar
• de Jong RG, Burden AM, de Kort S, et al. No decreased risk of gastrointestinal cancers in users of metformin in the Netherlands; a time-varying analysis of metformin exposure. Cancer Preve Res. 2017;10(5):290–297.
   PubMed Web of Science ®Google Scholar
• Cheung KS, Chan EW, Wong AYS, et al. Metformin use and gastric cancer risk in diabetic patients after helicobacter pylori eradication. J Natl Cancer Inst. 2019;111(5):484–489.30329127
   PubMedGoogle Scholar
• Zheng J, Xie SH, Santoni G, Lagergren J. Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study. Br J Cancer. 2019;121(10):877–882.31591459
   PubMed Web of Science ®Google Scholar
• Dulskas A, Patasius A, Kaceniene A, et al. Study of antihyperglycemic medication exposure and gastric cancer risk. J Clin Med. 2020;9(2):435.
   PubMed Web of Science ®Google Scholar
• Shuai Y, Li C, Zhou X. The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis. Clin Transl Oncol. 2020:1–11.31127471
   PubMed Web of Science ®Google Scholar
• Coyle C, Cafferty FH, Vale C, Langley RE. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–2195.27681864
   PubMed Web of Science ®Google Scholar
• Gandini S, Puntoni M, Heckman-Stoddard BM, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Preve Res. 2014;7(9):867–885.
   PubMed Web of Science ®Google Scholar
• Lee CK, Jung M, Jung I, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg. 2016;263(1):96–102.25575260
   PubMed Web of Science ®Google Scholar
• Lacroix O, Couttenier A, Vaes E, Cardwell CR, De Schutter H, Robert A. Impact of metformin on gastric adenocarcinoma survival: a Belgian population based study. Cancer Epidemiol. 2018;53:149–155.29453032
   PubMed Web of Science ®Google Scholar
• Seo HS, Jung YJ, Kim JH, Lee HH, Park CH. The effect of metformin on prognosis in patients with locally advanced gastric cancer associated with type 2 diabetes mellitus. Am J Clin Oncol. 2019;42(12):909–917.31693512
   PubMed Web of Science ®Google Scholar
• Baglia ML, Cui Y, Zheng T, et al. Diabetes Medication use in association with survival among patients of breast, colorectal, lung, or gastric cancer. Cancer Res Treat. 2019;51(2):538–546.29986576
   PubMed Web of Science ®Google Scholar
• Kwon Y, Abdemur A, Lo ME, Park S, Szomstein S, Rosenthal RJ. The foregut theory as a possible mechanism of action for the remission of type 2 diabetes in low body mass index patients undergoing subtotal gastrectomy for gastric cancer. Surg Obes Relat Dis. 2014;10(2):235–242.24496047
   PubMed Web of Science ®Google Scholar
• An JY, Kim YM, Yun MA, Jeon BH, Noh SH. Improvement of type 2 diabetes mellitus after gastric cancer surgery: short-term outcome analysis after gastrectomy. World J Gastroenterol. 2013;19(48):9410–9417.24409070
   PubMed Web of Science ®Google Scholar
• Greenhill C. Gastric cancer. Metformin improves survival and recurrence rate in patients with diabetes and gastric cancer. Nat Rev Gastroenterol Hepatol. 2015;12(3):124.
   PubMedGoogle Scholar
• Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23(1):27–47.26771115
   PubMed Web of Science ®Google Scholar
• Foretz M, Viollet B. New promises for metformin: advances in the understanding of its mechanisms of action. Med Sci (Paris). 2014;30(1):82–92.24472464
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Komeil I, Huttunen J, Sikora J, Huttunen KM. Effective cellular transport of ortho-halogenated sulfonamide derivatives of metformin is related to improved antiproliferative activity and apoptosis induction in MCF-7 cells. Int J Mol Sci. 2020;21:7.
   Web of Science ®Google Scholar
• Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014;2:12.25184038
   PubMedGoogle Scholar
• Griss T, Vincent EE, Egnatchik R, et al. Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol. 2015;13(12):e1002309.26625127
   PubMed Web of Science ®Google Scholar
• Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8(10):774–785.17712357
   PubMed Web of Science ®Google Scholar
• Daugan M, Dufay Wojcicki A, d’Hayer B, Boudy V. Metformin: an anti-diabetic drug to fight cancer. Pharmacol Res. 2016;113(Pt A):675–685.27720766
   PubMedGoogle Scholar
• Andrzejewski S, Siegel PM, St-Pierre J. Metabolic profiles associated with metformin efficacy in cancer. Front Endocrinol (Lausanne). 2018;9:372.30186229
   PubMed Web of Science ®Google Scholar
• Woods A, Johnstone SR, Dickerson K, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003;13(22):2004–2008.14614828
   PubMed Web of Science ®Google Scholar
• Hawley SA, Boudeau J, Reid JL, et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol. 2003;2(4):28.14511394
   PubMedGoogle Scholar
• Woods A, Dickerson K, Heath R, et al. Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab. 2005;2(1):21–33.16054096
   PubMed Web of Science ®Google Scholar
• Hawley SA, Pan DA, Mustard KJ, et al. Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2005;2(1):9–19.16054095
   PubMed Web of Science ®Google Scholar
• Neumann D. Is TAK1 a direct upstream kinase of AMPK? Int J Mol Sci. 2018;19(8):2412.
   PubMed Web of Science ®Google Scholar
• Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem. 2006;281(35):25336–25343.16835226
   PubMed Web of Science ®Google Scholar
• Del Barco S, Vazquez-Martin A, Cufi S, et al. Metformin: multi-faceted protection against cancer. Oncotarget. 2011;2(12):896–917.22203527
   PubMedGoogle Scholar
• Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014;10(3):143–156.24393785
   PubMed Web of Science ®Google Scholar
• Minassian C, Tarpin S, Mithieux G. Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin. Biochem Pharmacol. 1998;55(8):1213–1219.9719475
   PubMed Web of Science ®Google Scholar
• Pollak M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med. 2014;20(6):591–593.24901568
   PubMedGoogle Scholar
• Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012;29(2):1314–1327.21301998
   PubMed Web of Science ®Google Scholar
• Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol. 2015;11(1):9–15.25517383
   PubMed Web of Science ®Google Scholar
• Kato K, Gong J, Iwama H, et al. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther. 2012;11(3):549–560.22222629
   PubMed Web of Science ®Google Scholar
• Loubiere C, Goiran T, Laurent K, Djabari Z, Tanti JF, Bost F. Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. Oncotarget. 2015;6(17):15652–15661.26002551
   PubMedGoogle Scholar
• Fang W, Cui H, Yu D, Chen Y, Wang J, Yu G. Increased expression of phospho-acetyl-CoA carboxylase protein is an independent prognostic factor for human gastric cancer without lymph node metastasis. Med Oncol. 2014;31(7):15.24924473
   PubMed Web of Science ®Google Scholar
• Courtois S, Lehours P, Bessede E. The therapeutic potential of metformin in gastric cancer. Gastric Cancer. 2019;22(4):653–662.30900101
   PubMed Web of Science ®Google Scholar
• Chang HR, Nam S, Kook MC, et al. HNF4alpha is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer. Gut. 2016;65(1):19–32.25410163
   PubMed Web of Science ®Google Scholar
• Nam S, Chang HR, Kim KT, et al. PATHOME: an algorithm for accurately detecting differentially expressed subpathways. Oncogene. 2014;33(41):4941–4951.24681952
   PubMed Web of Science ®Google Scholar
• Zhou J, Yang Z, Tsuji T, et al. LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene. 2011;30(16):1892–1900.21217782
   PubMed Web of Science ®Google Scholar
• Huang D, He X, Zou J, et al. Negative regulation of Bmi-1 by AMPK and implication in cancer progression. Oncotarget. 2016;7(5):6188–6200.26717043
   PubMedGoogle Scholar
• Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004;113(2):175–179.14722607
   PubMed Web of Science ®Google Scholar
• De Luise M, Guarnieri V, Ceccarelli C, et al. DNA mutation associates with dysfunction of HIF1alpha in a von hippel-lindau renal oncocytoma. J Diabetes Res. 2019;2019:8069583.
   Google Scholar
• Yu G, Fang W, Xia T, et al. Metformin potentiates rapamycin and cisplatin in gastric cancer in mice. Oncotarget. 2015;6(14):12748–12762.25909163
   PubMedGoogle Scholar
• Han G, Gong H, Wang Y, Guo S, Liu K. AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell. Cancer Biol Ther. 2015;16(1):77–87.25456211
   PubMed Web of Science ®Google Scholar
• Lu CC, Chiang JH, Tsai FJ, et al. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol. 2019;54(4):1271–1281.30720062
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664–3671.23999440
   PubMed Web of Science ®Google Scholar
• Chen G, Feng W, Zhang S, et al. Metformin inhibits gastric cancer via the inhibition of HIF1alpha/PKM2 signaling. Am J Cancer Res. 2015;5(4):1423–1434.26101707
   PubMed Web of Science ®Google Scholar
• Lesan V, Ghaffari SH, Salaramoli J, et al. Evaluation of antagonistic effects of metformin with cisplatin in gastric cancer cells. Int J Hematol Oncol Stem Cell Res. 2014;8(3):12–19.
   PubMedGoogle Scholar
• Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392(6672):190–193.9515965
   PubMed Web of Science ®Google Scholar
• Garcia de Herreros A, Baulida J. Cooperation, amplification, and feed-back in epithelial-mesenchymal transition. Biochim Biophys Acta. 2012;1825(2):223–228.22306657
   PubMed Web of Science ®Google Scholar
• Valaee S, Yaghoobi MM, Shamsara M. Metformin inhibits gastric cancer cells metastatic traits through suppression of epithelial-mesenchymal transition in a glucose-independent manner. PLoS One. 2017;12(3):e0174486.28334027
   PubMed Web of Science ®Google Scholar
• Jun KH, Lee JE, Kim SH, et al. Clinicopathological significance of N-cadherin and VEGF in advanced gastric cancer brain metastasis and the effects of metformin in preclinical models. Oncol Rep. 2015;34(4):2047–2053.26260219
   PubMed Web of Science ®Google Scholar
• Funato K, Yamazumi Y, Oda T, Akiyama T. Tyrosine phosphatase PTPRD suppresses colon cancer cell migration in coordination with CD44. Exp Ther Med. 2011;2(3):457–463.22977525
   PubMed Web of Science ®Google Scholar
• Bae WJ, Ahn JM, Byeon HE, Kim S, Lee D. PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin. J Exp Clin Cancer Res. 2019;38(1):484.31805999
   PubMed Web of Science ®Google Scholar
• Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NFkappaB activity in malignant melanoma. Oncogene. 2004;23(52):8509–8519.15378016
   PubMed Web of Science ®Google Scholar
• Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178–196.24556840
   PubMed Web of Science ®Google Scholar
• Sekino N, Kano M, Matsumoto Y, et al. The antitumor effects of metformin on gastric cancer in vitro and on peritoneal metastasis. Anticancer Res. 2018;38(11):6263–6269.30396946
   PubMed Web of Science ®Google Scholar
• Lei Y, Yi Y, Liu Y, et al. Metformin targets multiple signaling pathways in cancer. Chin J Cancer. 2017;36(1):17.28126011
   PubMedGoogle Scholar
• Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med. 2007;58:267–284.17002552
   PubMed Web of Science ®Google Scholar
• Courtois S, Duran RV, Giraud J, et al. Metformin targets gastric cancer stem cells. Eur J Cancer. 2017;84:193–201.28822889
   PubMed Web of Science ®Google Scholar
• Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 2003;3(12):903–911.14737121
   PubMed Web of Science ®Google Scholar
• Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell. 2008;15(6):801–812.19081070
   PubMed Web of Science ®Google Scholar
• Song Z, Yue W, Wei B, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One. 2011;6(3):e17687.21394208
   PubMed Web of Science ®Google Scholar
• Song Z, Wei B, Lu C, Huang X, Li P, Chen L. Metformin suppresses the expression of Sonic hedgehog in gastric cancer cells. Mol Med Rep. 2017;15(4):1909–1915.28260041
   PubMed Web of Science ®Google Scholar
• Grainger S, Hryniuk A, Lohnes D. Cdx1 and Cdx2 exhibit transcriptional specificity in the intestine. PLoS One. 2013;8(1):e54757.23382958
   PubMed Web of Science ®Google Scholar
• Choi SI, Yoon C, Park MR, et al. CDX1 expression induced by CagA-expressing helicobacter pylori promotes gastric tumorigenesis. Mol Cancer Res. 2019;17(11):2169–2183.31416838
   PubMed Web of Science ®Google Scholar
• Li W, Wong CC, Zhang X, et al. CAB39L elicited an anti-warburg effect via a LKB1-AMPK-PGC1alpha axis to inhibit gastric tumorigenesis. Oncogene. 2018;37(50):6383–6398.30054562
   PubMed Web of Science ®Google Scholar
• Miao ZF, Adkins-Threats M, Burclaff JR, et al. A metformin-responsive metabolic pathway controls distinct steps in gastric progenitor fate decisions and maturation. Cell Stem Cell. 2020.
   Web of Science ®Google Scholar
• Stocker SL, Morrissey KM, Yee SW, et al. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clin Pharmacol Ther. 2013;93(2):186–194.23267855
   PubMed Web of Science ®Google Scholar
• Segal ED, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun. 2011;414(4):694–699.21986525
   PubMed Web of Science ®Google Scholar
• Dong TS, Chang HH, Hauer M, et al. Metformin alters the duodenal microbiome and decreases the incidence of pancreatic ductal adenocarcinoma promoted by diet-induced obesity. Am J Physiol Gastrointest Liver Physiol. 2019;317(6):G763–G772.31545922
   PubMed Web of Science ®Google Scholar
• Jones GR, Molloy MP. Metformin, Microbiome and protection against colorectal cancer. Dig Dis Sci. 2020:1–6.31598920
   PubMed Web of Science ®Google Scholar